<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">34803167</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2059-3635</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Nov</Month>
              <Day>22</Day>
            </PubDate>
          </JournalIssue>
          <Title>Signal transduction and targeted therapy</Title>
          <ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Circulating tumor cells: biology and clinical significance.</ArticleTitle>
        <Pagination>
          <StartPage>404</StartPage>
          <MedlinePgn>404</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">404</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-021-00817-8</ELocationID>
        <Abstract>
          <AbstractText>Circulating tumor cells (CTCs) are tumor cells that have sloughed off the primary tumor and extravasate into and circulate in the blood. Understanding of the metastatic cascade of CTCs has tremendous potential for the identification of targets against cancer metastasis. Detecting these very rare CTCs among the massive blood cells is challenging. However, emerging technologies for CTCs detection have profoundly contributed to deepening investigation into the biology of CTCs and have facilitated their clinical application. Current technologies for the detection of CTCs are summarized herein, together with their advantages and disadvantages. The detection of CTCs is usually dependent on molecular markers, with the epithelial cell adhesion molecule being the most widely used, although molecular markers vary between different types of cancer. Properties associated with epithelial-to-mesenchymal transition and stemness have been identified in CTCs, indicating their increased metastatic capacity. Only a small proportion of CTCs can survive and eventually initiate metastases, suggesting that an interaction and modulation between CTCs and the hostile blood microenvironment is essential for CTC metastasis. Single-cell sequencing of CTCs has been extensively investigated, and has enabled researchers to reveal the genome and transcriptome of CTCs. Herein, we also review the clinical applications of CTCs, especially for monitoring response to cancer treatment and in evaluating prognosis. Hence, CTCs have and will continue to contribute to providing significant insights into metastatic processes and will open new avenues for useful clinical applications.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lin</LastName>
            <ForeName>Danfeng</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Shen</LastName>
            <ForeName>Lesang</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Luo</LastName>
            <ForeName>Meng</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Zhang</LastName>
            <ForeName>Kun</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Jinfan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yang</LastName>
            <ForeName>Qi</ForeName>
            <Initials>Q</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pathology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Fangfang</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Dan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Surgery, Traditional Chinese Medical Hospital of Zhuji, Shaoxing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zheng</LastName>
            <ForeName>Shu</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Yiding</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ydchen@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. ydchen@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Jiaojiao</ForeName>
            <Initials>J</Initials>
            <Identifier Source="ORCID">0000-0003-0442-6183</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Breast Surgery, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. zhoujj@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. zhoujj@zju.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Signal Transduct Target Ther</MedlineTA>
        <NlmUniqueID>101676423</NlmUniqueID>
        <ISSNLinking>2059-3635</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014408">Biomarkers, Tumor</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D014408" MajorTopicYN="N">Biomarkers, Tumor</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058750" MajorTopicYN="Y">Epithelial-Mesenchymal Transition</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009360" MajorTopicYN="N">Neoplastic Cells, Circulating</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>22</Day>
          <Hour>6</Hour>
          <Minute>30</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34803167</ArticleId>
        <ArticleId IdType="pmc">PMC8606574</ArticleId>
        <ArticleId IdType="doi">10.1038/s41392-021-00817-8</ArticleId>
        <ArticleId IdType="pii">10.1038/s41392-021-00817-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sethi N, Kang Y. Unravelling the complexity of metastasis-molecular understanding and targeted therapies. Nat. Rev. Cancer. 2011;11:735–748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21941285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670–691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5308465</ArticleId>
            <ArticleId IdType="pubmed">28187288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paget S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 1989;8:98–101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2673568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jones S, et al.  Comparative lesion sequencing provides insights into tumor evolution. Proc. Natl Acad. Sci. USA. 2008;105:4283–4288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2393770</ArticleId>
            <ArticleId IdType="pubmed">18337506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ley TJ, et al.  DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456:66–72.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2603574</ArticleId>
            <ArticleId IdType="pubmed">18987736</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosseini H, et al.  Early dissemination seeds metastasis in breast cancer. Nature. 2016;540:552–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5390864</ArticleId>
            <ArticleId IdType="pubmed">27974799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen S, et al.  Genome-wide CRISPR screen in a mouse model of tumor growth and metastasis. Cell. 2015;160:1246–1260.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4380877</ArticleId>
            <ArticleId IdType="pubmed">25748654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Navin N, et al.  Tumour evolution inferred by single-cell sequencing. Nature. 2011;472:90–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4504184</ArticleId>
            <ArticleId IdType="pubmed">21399628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu M, et al.  Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339:580–584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3760262</ArticleId>
            <ArticleId IdType="pubmed">23372014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peinado H, et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat. Med. 2012;18:883–891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3645291</ArticleId>
            <ArticleId IdType="pubmed">22635005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aceto N, et al.  Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158:1110–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4149753</ArticleId>
            <ArticleId IdType="pubmed">25171411</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 2013;19:1423–1437.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3954707</ArticleId>
            <ArticleId IdType="pubmed">24202395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ashworth TR. A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Australas. Med. J. 1869;14:146–149.</Citation>
        </Reference>
        <Reference>
          <Citation>Pantel K, Speicher MR. The biology of circulating tumor cells. Oncogene. 2016;35:1216–1224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26050619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alix-Panabieres C, Pantel K. Challenges in circulating tumour cell research. Nat. Rev. Cancer. 2014;14:623–631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25154812</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harper KL, et al.  Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature. 2016;540:588–592.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5471138</ArticleId>
            <ArticleId IdType="pubmed">27974798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosseini H, et al.  Early dissemination seeds metastasis in breast cancer. Nature. 2016;540:552–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5390864</ArticleId>
            <ArticleId IdType="pubmed">27974799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin. Chem. 2011;57:1242–1255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21784769</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thanh Huong P, et al.  Emerging role of circulating tumor cells in gastric cancer. Cancers. 2020;12:695–716.</Citation>
        </Reference>
        <Reference>
          <Citation>Gires O, Pan M, Schinke H, Canis M, Baeuerle PA. Expression and function of epithelial cell adhesion molecule EpCAM: where are we after 40 years? Cancer Metastasis Rev. 2020;39:969–987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7497325</ArticleId>
            <ArticleId IdType="pubmed">32507912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Popovic D, Vucic D, Dikic I. Ubiquitination in disease pathogenesis and treatment. Nat. Med. 2014;20:1242–1253.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25375928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Criscitiello C, Sotiriou C, Ignatiadis M. Circulating tumor cells and emerging blood biomarkers in breast cancer. Curr. Opin. Oncol. 2010;22:552–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20706122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gorin MA, et al.  Circulating tumour cells as biomarkers of prostate, bladder, and kidney cancer. Nat. Rev. Urol. 2017;14:90–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27872478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Varillas JI, et al.  Microfluidic isolation of circulating tumor cells and cancer stem-like cells from patients with pancreatic ductal adenocarcinoma. Theranostics. 2019;9:1417–1425.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6401494</ArticleId>
            <ArticleId IdType="pubmed">30867841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marcuello M, et al.  Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol. Asp. Med. 2019;69:107–122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31189073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia W, et al.  In vivo coinstantaneous identification of hepatocellular carcinoma circulating tumor cells by dual-targeting magnetic-fluorescent nanobeads. Nano Lett. 2021;21:634–641.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33264027</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. Mol. cancer. 2019;18:114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6607541</ArticleId>
            <ArticleId IdType="pubmed">31269959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gall TMH, Belete S, Khanderia E, Frampton AE, Jiao LR. Circulating tumor cells and cell-free DNA in pancreatic ductal adenocarcinoma. Am. J. Pathol. 2019;189:71–81.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30558725</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eslami SZ, Cortes-Hernandez LE, Alix-Panabieres C. Epithelial cell adhesion molecule: an anchor to isolate clinically relevant circulating tumor cells. Cells. 2020;9:1836–1852.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7464831</ArticleId>
            <ArticleId IdType="pubmed">32764280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, et al.  Label-free isolation and mRNA detection of circulating tumor cells from patients with metastatic lung cancer for disease diagnosis and monitoring therapeutic efficacy. Anal. Chem. 2015;87:11893–11900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26531886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ZL, et al.  High-efficiency isolation and rapid identification of heterogeneous circulating tumor cells (CTCS) using dual-antibody-modified fluorescent-magnetic nanoparticles. ACS Appl. Mater. Interface. 2019;11:39586–39593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31577122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, et al.  Antifouling hydrogel-coated magnetic nanoparticles for selective isolation and recovery of circulating tumor cells. J. Mater. Chem. B. 2021;9:677–682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33333542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reduzzi C, et al.  A novel circulating tumor cell subpopulation for treatment monitoring and molecular characterization in biliary tract cancer. Int J. Cancer. 2020;146:3495–3503.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7217035</ArticleId>
            <ArticleId IdType="pubmed">31814120</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mittal V. Epithelial mesenchymal transition in tumor metastasis. Annu. Rev. Pathol. 2018;13:395–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29414248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okabe T, et al.  Mesenchymal characteristics and predictive biomarkers on circulating tumor cells for therapeutic strategy. Cancers. 2020;12:3588–3610.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7761066</ArticleId>
            <ArticleId IdType="pubmed">33266262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu J, et al.  Using single-cell sequencing technology to detect circulating tumor cells in solid tumors. Mol. Cancer. 2021;20:104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8375060</ArticleId>
            <ArticleId IdType="pubmed">34412644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wulfing P, et al.  HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin. Cancer Res. 2006;12:1715–1720.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16551854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayashi N, et al.  Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer. Int J. Clin. Oncol. 2012;17:96–104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3860324</ArticleId>
            <ArticleId IdType="pubmed">21671160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Beije N, et al.  Prognostic impact of HER2 and ER status of circulating tumor cells in metastatic breast cancer patients with a HER2-negative primary tumor. Neoplasia. 2016;18:647–653.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5071539</ArticleId>
            <ArticleId IdType="pubmed">27764697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang CH, Chang CJ, Yeh KY, Chang PH, Huang JS. The prognostic value of HER2-positive circulating tumorcells in breast cancer patients: a systematic review and meta-analysis. Clin. Breast Cancer. 2017;17:341–349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28347604</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaeger BAS, et al.  The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: a translationalresearch project of a prospective randomized phase III trial. PLoS One. 2017;12:e0173593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5460789</ArticleId>
            <ArticleId IdType="pubmed">28586395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brouwer A, et al.  HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: a comparative study oncharacterization techniques. PLoS One. 2019;14:e0220906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6726188</ArticleId>
            <ArticleId IdType="pubmed">31483799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen W, et al.  Detection of HER2-positive circulating tumor cells using the liquidbiopsy system in breast cancer. Clin. Breast Cancer. 2019;19:e239–e246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30472074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacot W, et al.  Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCeT-DM1 trial. Breast Cancer Res. 2019;21:121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6854749</ArticleId>
            <ArticleId IdType="pubmed">31727113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nanou A, Zeune LL, Bidard FC, Pierga JY, Terstappen L. HER2 expression on tumor-derived extracellularvesicles and circulating tumor cells in metastatic breast cancer. Breast Cancer Res. 2020;22:86.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7424685</ArticleId>
            <ArticleId IdType="pubmed">32787900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, et al.  Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients withHER2-negative tumors. Breast Cancer Res. Treat. 2020;181:679–689.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7299127</ArticleId>
            <ArticleId IdType="pubmed">32367460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishima Y, et al.  Detection of HER2 amplification in circulating tumor cells of HER2-negative gastric cancer patients. Target Oncol. 2017;12:341–351.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28508152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gradilone A, et al.  Circulating tumor cells (CTCs) in metastatic breast cancer (MBC): prognosis, drug resistance andphenotypic characterization. Ann. Oncol. 2011;22:86–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20603432</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Somlo G, et al.  Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary andmetastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology. Breast Cancer Res. Treat. 2011;128:155–163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3543871</ArticleId>
            <ArticleId IdType="pubmed">21499685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Forsare C, et al.  Evolution of estrogen receptor status from primary tumors to metastasis and serially collected circulating tumor cells. Int. J. Mol. Sci. 2020;21:2885–2897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7215368</ArticleId>
            <ArticleId IdType="pubmed">32326116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Todenhofer T, et al.  Preliminary experience on the use of the adnatest (R) system for detection of circulating tumor cells inprostate cancer patients. Anticancer Res. 2012;32:3507–3513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22843938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friedlander TW, et al.  Detection and characterization of invasive circulating tumor cells derived from men with metastaticcastration-resistant prostate cancer. Int. J. Cancer. 2014;134:2284–2293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24166007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin C, et al.  Molecular profiling of pooled circulating tumor cells from prostate cancer patients using a dual-antibodyfunctionalizedmicrofluidic device. Anal. Chem. 2018;90:3744–3751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29464943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen L, et al.  Combined use of EpCAM and FRalpha enables the high-efficiency capture of circulating tumor cells in nonsmallcell lung cancer. Sci. Rep. 2018;8:1188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5775318</ArticleId>
            <ArticleId IdType="pubmed">29352248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, et al.  Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-linepemetrexed-based chemotherapy in patients with non-squamous non-small cell lung cancer. Ann. Transl. Med. 2020;8:631.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7290650</ArticleId>
            <ArticleId IdType="pubmed">32566568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei S, et al.  Effect of vein-first vs artery-first surgical technique on circulating tumor cells and survival in patients with nonsmallcell lung cancer: a randomized clinical trial and registry-based propensity score matching analysis. JAMA Surg. 2019;154:e190972.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6495366</ArticleId>
            <ArticleId IdType="pubmed">31042283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao W, et al.  Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrencefollowing curative resection of gastric cancer. J. Surg. Oncol. 2011;103:110–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21259243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krishnamurthy S, et al.  Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients withoperable breast cancer. Cancer Med. 2013;2:226–233.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3639661</ArticleId>
            <ArticleId IdType="pubmed">23634290</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidard FC, et al.  Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastaticuveal melanoma. Int. J. Cancer. 2014;134:1207–1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23934701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bettegowda C, et al.  Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014;6:224ra224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4017867</ArticleId>
            <ArticleId IdType="pubmed">24553385</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lucci A, et al.  Circulating tumor cells and early relapse in node-positive melanoma. Clin. Cancer Res. 2020;26:1886–1895.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32015020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshimoto S, et al.  Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy aftercomplete resection of stage IV melanoma. Ann. Surg. 2012;255:357–362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3320770</ArticleId>
            <ArticleId IdType="pubmed">22202581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoshimoto S, et al.  Association between circulating tumor cells and prognosis in patients with stage III melanoma withsentinel lymph node metastasis in a phase III international multicenter trial. J. Clin. Oncol. 2012;30:3819–3826.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3478576</ArticleId>
            <ArticleId IdType="pubmed">23008288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiniwa Y, et al.  Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAFmutation. BMC Cancer. 2021;21:287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7968258</ArticleId>
            <ArticleId IdType="pubmed">33731038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall CS, et al.  Circulating tumor cells in stage IV melanoma patients. J. Am. Coll. Surg. 2018;227:116–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29746918</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lin SY, et al.  Prospective molecular profiling of circulating tumor cells from patients with melanoma receivingcombinatorial immunotherapy. Clin. Chem. 2020;66:169–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7193771</ArticleId>
            <ArticleId IdType="pubmed">31672856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maheswaran S, et al.  Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 2008;359:366–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3551471</ArticleId>
            <ArticleId IdType="pubmed">18596266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fabbri F, et al.  Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRASmutation status in pure CTCs. Cancer Lett. 2013;335:225–231.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23419522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buim ME, et al.  Detection of KRAS mutations in circulating tumor cells from patients with metastatic colorectal cancer. Cancer Biol. Ther. 2015;16:1289–1295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4622515</ArticleId>
            <ArticleId IdType="pubmed">26252055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalikaki A, et al.  KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectalcancer. PloS One. 2014;9:e104902.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4138105</ArticleId>
            <ArticleId IdType="pubmed">25137394</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kondo Y, et al.  KRAS mutation analysis of single circulating tumor cells from patients with metastatic colorectal cancer. BMC Cancer. 2017;17:311.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5415811</ArticleId>
            <ArticleId IdType="pubmed">28468669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kulemann B, et al.  Pancreatic cancer: circulating tumor cells and primary tumors show heterogeneous KRAS mutations. Sci. Rep. 2017;7:4510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5495768</ArticleId>
            <ArticleId IdType="pubmed">28674438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lohr JG, et al.  Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer. Nat. Biotechnol. 2014;32:479–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4034575</ArticleId>
            <ArticleId IdType="pubmed">24752078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faugeroux V, et al.  An accessible and unique insight into metastasis mutational content through whole-exome sequencing ofcirculating tumor cells in metastatic prostate cancer. Eur. Urol. Oncol. 2020;3:498–508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31412010</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deng G, et al.  Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. BMC Cancer. 2014;14:456–467.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4071027</ArticleId>
            <ArticleId IdType="pubmed">24947048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fernandez V, et al.  TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breastcancer patients. Breast Cancer Res. 2014;16:445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4303125</ArticleId>
            <ArticleId IdType="pubmed">25307991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kelley RK, et al.  Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and nextgenerationsequencing in cases and controls. BMC Cancer. 2015;15:206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4399150</ArticleId>
            <ArticleId IdType="pubmed">25884197</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ni X, et al.  Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients. Proc. Natl Acad. Sci. USA. 2013;110:21083–21088.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3876226</ArticleId>
            <ArticleId IdType="pubmed">24324171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carter L, et al.  Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients withchemosensitive and chemorefractory small-cell lung cancer. Nat. Med. 2017;23:114–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27869802</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paoletti C, et al.  Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cellsdocuments heterogeneous resistance mechanisms. Cancer Res. 2018;78:1110–1122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5815882</ArticleId>
            <ArticleId IdType="pubmed">29233927</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortolan E, et al.  Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvantchemotherapy. ESMO Open. 2021;6:100086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8010400</ArticleId>
            <ArticleId IdType="pubmed">33743331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lambros MB, et al.  Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis. Clin. Cancer Res.: . J. Am. Assoc. Cancer Res. 2018;24:5635–5644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30093450</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S, et al.  Whole genomic copy number alterations in circulating tumor cells from men with abiraterone orenzalutamide-resistant metastatic castration-resistant prostate cancer. Clin. Cancer Res.: . J. Am. Assoc. Cancer Res. 2017;23:1346–1357.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27601596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Malihi PD, et al.  Single-cell circulating tumor cell analysis reveals genomic instability as a distinctive feature of aggressiveprostate cancer. Clin. Cancer Res.: . J. Am. Assoc. Cancer Res. 2020;26:4143–4153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8043601</ArticleId>
            <ArticleId IdType="pubmed">32341031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pailler E, et al.  Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-celllung cancer. J. Clin. Oncol. 2013;31:2273–2281.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23669222</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer JA, et al.  FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEEplatform. Cancer Genet. 2011;204:589–595.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22200084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frithiof H, Aaltonen K, Ryden L. A FISH-based method for assessment of HER-2 amplification status in breast cancercirculating tumor cells following CellSearch isolation. OncoTargets Ther. 2016;9:7095–7103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5117892</ArticleId>
            <ArticleId IdType="pubmed">27895501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gkountela S, et al.  Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell. 2019;176:98–112.e114.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6363966</ArticleId>
            <ArticleId IdType="pubmed">30633912</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong Y, Wang Z, Shi Q. Liquid biopsy based single-cell transcriptome profiling characterizes heterogeneity ofdisseminated tumor cells from lung adenocarcinoma. Proteomics. 2020;20:e1900224.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31960581</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magbanua MJM, et al.  Expanded genomic profiling of circulating tumor cells in metastatic breast cancer patients to assessbiomarker status and biology over time (CALGB 40502 and CALGB 40503, Alliance) Clin. Cancer Res.: . J. Am. Assoc. Cancer Res. 2018;24:1486–1499.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5856614</ArticleId>
            <ArticleId IdType="pubmed">29311117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Y-H, et al.  Hydro-Seq enables contamination-free high-throughput single-cell RNA-sequencing for circulating tumor cells. Nat. Commun. 2019;10:2163–2173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6520360</ArticleId>
            <ArticleId IdType="pubmed">31092822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miyamoto D, et al.  RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349:1351–1356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4872391</ArticleId>
            <ArticleId IdType="pubmed">26383955</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbazan J, et al.  Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. PloS One. 2012;7:e40476.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3397799</ArticleId>
            <ArticleId IdType="pubmed">22811761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kallergi G, et al.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastaticbreast cancer patients. Breast Cancer Res. 2011;13:R59.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3218948</ArticleId>
            <ArticleId IdType="pubmed">21663619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Balasubramanian P, et al.  Multiparameter analysis, including EMT markers, on negatively enriched blood samples frompatients with squamous cell carcinoma of the head and neck. PLoS One. 2012;7:e42048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3406036</ArticleId>
            <ArticleId IdType="pubmed">22844540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Theodoropoulos PA, et al.  Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients withbreast cancer. Cancer Lett. 2010;288:99–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19619935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong AJ, et al.  Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelialand mesenchymal markers. Mol. Cancer Res. 2011;9:997–1007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3157566</ArticleId>
            <ArticleId IdType="pubmed">21665936</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu X, et al.  Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source ofmetastasis. Sci. Adv. 2019;5:eaav4275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6584608</ArticleId>
            <ArticleId IdType="pubmed">31223646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thiery JP, Lim CT. Tumor dissemination: an EMT affair. Cancer Cell. 2013;23:272–273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23518345</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pecot CV, et al.  A novel platform for detection of CK+ and CK- CTCs. Cancer Discov. 2011;1:580–586.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3237635</ArticleId>
            <ArticleId IdType="pubmed">22180853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun YF, et al.  Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial andmesenchymal composition and distinct clinical significance in hepatocellular carcinoma. Clin. Cancer Res.: . J. Am. Assoc. Cancer Res. 2018;24:547–559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29070526</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu L, et al.  The novel association of circulating tumor cells and circulating megakaryocytes with prostate cancer prognosis. Clin. Cancer Res. 2017;23:5112–5122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28615267</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications forcancer. Nat. Rev. Mol. Cell Bio. 2019;20:69–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30459476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan Y, et al.  Identification of key genes and functions of circulating tumor cells in multiple cancers through bioinformaticanalysis. BMC Med. Genom. 2020;13:140.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7513313</ArticleId>
            <ArticleId IdType="pubmed">32972417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tashireva LA, et al.  Heterogeneous manifestations of epithelial-mesenchymal plasticity of circulating tumor cells in breast cancer patients. Int. J. Mol. Sci. 2021;22:2504–2521.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7958863</ArticleId>
            <ArticleId IdType="pubmed">33801519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xin Y, Li K, Yang M, Tan Y. Fluid shear stress induces EMT of circulating tumor cells via jnk signaling in favor of their survival during hematogenous dissemination. Int. J. Mol. Sci. 2020;21:8115–8130.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7663710</ArticleId>
            <ArticleId IdType="pubmed">33143160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Horimoto Y, et al.  Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status duringeribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study. J. Transl. Med. 2018;16:287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6195982</ArticleId>
            <ArticleId IdType="pubmed">30342534</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guan XW, et al.  The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer. CancerCommun. 2019;39:1–10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6319003</ArticleId>
            <ArticleId IdType="pubmed">30606259</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lindsay CR, et al.  A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecularsubgroups. Ann. Oncol. 2017;28:1523–1531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28633480</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satelli A, et al.  Epithelial-mesenchymal transitioned circulating tumor cells capture for detecting tumor progression. Clin. Cancer Res. 2015;21:899–906.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4334736</ArticleId>
            <ArticleId IdType="pubmed">25516888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brechbuhl HM, et al.  Analysis of circulating breast cancer cell heterogeneity and interactions with peripheral bloodmononuclear cells. Mol. Carcinog. 2020;59:1129–1139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7895311</ArticleId>
            <ArticleId IdType="pubmed">32822091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miklikova S, et al.  Inflammation-based scores increase the prognostic value of circulating tumor cells in primary breast cancer. Cancers. 2020;12:1134–1148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7281016</ArticleId>
            <ArticleId IdType="pubmed">32369910</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu Y, et al.  SUMOylation represses Nanog expression via modulating transcription factors Oct4 and Sox2. PloS One. 2012;7:e39606.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3382131</ArticleId>
            <ArticleId IdType="pubmed">22745796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang R, et al.  Co-expression of stem cell and epithelial mesenchymal transition markers in circulating tumor cells ofbladder cancer patients. OncoTargets Ther. 2020;13:10739–10748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7588836</ArticleId>
            <ArticleId IdType="pubmed">33122913</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao P, et al.  Establishment and characterization of a CTC cell line from peripheral blood of breast cancer patient. J. Cancer. 2019;10:6095–6104.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6856591</ArticleId>
            <ArticleId IdType="pubmed">31762819</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wan S, et al.  New labyrinth microfluidic device detects circulating tumor cells expressing cancer stem cell marker andcirculating tumor microemboli in hepatocellular carcinoma. Sci. Rep. 2019;9:18575.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6901480</ArticleId>
            <ArticleId IdType="pubmed">31819089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T, et al.  Circulating glioma cells exhibit stem cell-like properties. Cancer Res. 2018;78:6632–6642.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6497085</ArticleId>
            <ArticleId IdType="pubmed">30322863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin J, et al.  Circulating tumor cells enriched by the depletion of leukocytes with bi-antibodies in non-small cell lung cancer:potential clinical application. PloS One. 2015;10:e0137076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4552861</ArticleId>
            <ArticleId IdType="pubmed">26317979</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin J, Tang K, Xin Y, Zhang T, Tan Y. Hemodynamic shear flow regulates biophysical characteristics and functionsof circulating breast tumor cells reminiscent of brain metastasis. Soft Matter. 2018;14:9528–9533.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30468439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi H, et al.  Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3?activities. Breast Cancer Res. 2019;21:6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6335853</ArticleId>
            <ArticleId IdType="pubmed">30651129</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Follain G, et al.  Fluids and their mechanics in tumour transit: shaping metastasis. Nat. Rev. Cancer. 2020;20:107–124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31780785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strilic B, Offermanns S. Intravascular survival and extravasation of tumor cells. Cancer cell. 2017;32:282–293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28898694</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rejniak KA. Circulating tumor cells: when a solid tumor meets a fluid microenvironment. Adv. Exp. Med. Biol. 2016;936:93–106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5113997</ArticleId>
            <ArticleId IdType="pubmed">27739044</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garrido-Navas C, et al.  Cooperative and escaping mechanisms between circulating tumor cells and blood constituents. Cells. 2019;8:1382–1391.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6912439</ArticleId>
            <ArticleId IdType="pubmed">31684193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol. 2019;16:601–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31160735</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aliustaoglu M, et al.  The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancerbefore treatment. Med. Oncol. 2010;27:1060–1065.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19847679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu S, et al.  The preoperative peripheral blood monocyte count is associated with liver metastasis and overall survival incolorectal cancer patients. PloS One. 2016;11:e0157486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4927165</ArticleId>
            <ArticleId IdType="pubmed">27355390</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, et al.  Circulating neutrophils predict poor survival for HCC and promote HCC progression through p53 andSTAT3 signaling pathway. J. Cancer. 2020;11:3736–3744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7171508</ArticleId>
            <ArticleId IdType="pubmed">32328178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stott SL, et al.  Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc. Natl Acad. Sci. USA. 2010;107:18392–18397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2972993</ArticleId>
            <ArticleId IdType="pubmed">20930119</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szczerba BM, et al.  Neutrophils escort circulating tumour cells to enable cell cycle progression. Nature. 2019;566:553–557.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30728496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hattar K, et al.  Interactions between neutrophils and non-small cell lung cancer cells: enhancement of tumor proliferationand inflammatory mediator synthesis. Cancer Immunol., Immunother. 2014;63:1297–1306.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4255085</ArticleId>
            <ArticleId IdType="pubmed">25186613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spicer JD, et al.  Neutrophils promote liver metastasis via Mac-1-mediated interactions with circulating tumor cells. Cancer Res. 2012;72:3919–3927.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22751466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strell C, Lang K, Niggemann B, Zaenker KS, Entschladen F. Surface molecules regulating rolling and adhesion toendothelium of neutrophil granulocytes and MDA-MB-468 breast carcinoma cells and their interaction. Cell. Mol. life Sci. 2007;64:3306–3316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17994288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact withneutrophils to facilitate lung metastasis development. Cancer Res. 2010;70:6071–6082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2905495</ArticleId>
            <ArticleId IdType="pubmed">20610626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rowson-Hodel AR, et al.  Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficientmetastasis in a mouse model of breast cancer. Oncogene. 2018;37:197–207.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5930013</ArticleId>
            <ArticleId IdType="pubmed">28892049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen MB, et al.  Inflamed neutrophils sequestered at entrapped tumor cells via chemotactic confinement promote tumorcell extravasation. Proc. Natl Acad. Sci. USA. 2018;115:7022–7027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6142213</ArticleId>
            <ArticleId IdType="pubmed">29915060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masucci MT, Minopoli M, Del Vecchio S, Carriero MV. The emerging role of neutrophil extracellular traps (NETs)in tumor progression and metastasis. Front. Immunol. 2020;11:1749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7524869</ArticleId>
            <ArticleId IdType="pubmed">33042107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cools-Lartigue J, et al.  Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J. Clin. Investig. 2013;123:3446–3458.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3726160</ArticleId>
            <ArticleId IdType="pubmed">23863628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Najmeh S, et al.  Neutrophil extracellular traps sequester circulating tumor cells via ?1-integrin mediated interactions. Int. J. Cancer. 2017;140:2321–2330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28177522</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tohme S, et al.  Neutrophil extracellular traps promote the development and progression of liver metastases after surgicalstress. Cancer Res. 2016;76:1367–1380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4794393</ArticleId>
            <ArticleId IdType="pubmed">26759232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Albrengues J, et al.  Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science. 2018;361:1353–1367.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6777850</ArticleId>
            <ArticleId IdType="pubmed">30262472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiao Y, et al.  Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophilextracellular trap formation. Cancer Cell. 2021;39:423–437.e427.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33450198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  DNA of neutrophil extracellular traps promotes cancer metastasis via CCDC25. Nature. 2020;583:133–138.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32528174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, et al.  Circulating tumor-associated neutrophils (cTAN) contribute to circulating tumor cell survival by suppressingperipheral leukocyte activation. Tumour Biol.: J. Int. Soc. Oncodev. Biol. Med. 2016;37:5397–5404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26563367</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spiegel A, et al.  Neutrophils suppress intraluminal nk cell-mediated tumor cell clearance and enhance extravasation ofdisseminated carcinoma cells. Cancer Discov. 2016;6:630–649.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4918202</ArticleId>
            <ArticleId IdType="pubmed">27072748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumagai Y, et al.  Surgical stress increases circulating low-density neutrophils which may promote tumor recurrence. J. Surg. Res. 2020;246:52–61.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31561178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coffelt SB, et al.  IL-17-producing ?? T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522:345–348.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4475637</ArticleId>
            <ArticleId IdType="pubmed">25822788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doak GR, Schwertfeger KL, Wood DK. Distant relations: macrophage functions in the metastatic niche. TrendsCancer. 2018;4:445–459.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5990045</ArticleId>
            <ArticleId IdType="pubmed">29860988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton G, Rath B, Klameth L, Hochmair MJ. Small cell lung cancer: recruitment of macrophages by circulatingtumor cells. Oncoimmunology. 2016;5:e1093277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4839345</ArticleId>
            <ArticleId IdType="pubmed">27141354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hamilton G, Rath B. Circulating tumor cell interactions with macrophages: implications for biology and treatment. Transl. Lung Cancer Res. 2017;6:418–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5583067</ArticleId>
            <ArticleId IdType="pubmed">28904886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei C, et al.  Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulatingtumor cell-mediated colorectal cancer metastasis. Mol. Cancer. 2019;18:64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6441214</ArticleId>
            <ArticleId IdType="pubmed">30927925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osmulski PA, et al.  Contacts with macrophages promote an aggressive nanomechanical phenotype of circulating tumorcells in prostate cancer. Cancer Res. 2021;81:4110–4123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8367292</ArticleId>
            <ArticleId IdType="pubmed">34045187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shabo I, et al.  Macrophage traits in cancer cells are induced by macrophage-cancer cell fusion and cannot be explained bycellular interaction. BMC Cancer. 2015;15:922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4653907</ArticleId>
            <ArticleId IdType="pubmed">26585897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clawson GA, et al.  Macrophage-tumor cell fusions from peripheral blood of melanoma patients. PloS One. 2015;10:e0134320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4534457</ArticleId>
            <ArticleId IdType="pubmed">26267609</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clawson GA, et al.  “Stealth dissemination” of macrophage-tumor cell fusions cultured from blood of patients withpancreatic ductal adenocarcinoma. PloS One. 2017;12:e0184451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5619717</ArticleId>
            <ArticleId IdType="pubmed">28957348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manjunath Y, et al.  Tumor-cell-macrophage fusion cells as liquid biomarkers and tumor enhancers in cancer. Int. J. Mol. Sci. 2020;21:1872.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7084898</ArticleId>
            <ArticleId IdType="pubmed">32182935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gast CE, et al.  Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage andsurvival. Sci. Adv. 2018;4:eaat7828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6135550</ArticleId>
            <ArticleId IdType="pubmed">30214939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manjunath Y, et al.  Circulating giant tumor-macrophage fusion cells are independent prognosticators in patients withNSCLC. J. Thorac. Oncol.: . Publ. Int. Assoc. Study Lung Cancer. 2020;15:1460–1471.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32416323</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schlesinger M. Role of platelets and platelet receptors in cancer metastasis. J. Hematol. Oncol. 2018;11:125.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6180572</ArticleId>
            <ArticleId IdType="pubmed">30305116</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaertner F, Massberg S. Patrolling the vascular borders: platelets in immunity to infection and cancer. Nat. Rev. Immunol. 2019;19:747–760.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31409920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas GM, et al.  Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases theincidence of deep vein thrombosis in mice. J. thrombosis Haemost. 2015;13:1310–1319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4496280</ArticleId>
            <ArticleId IdType="pubmed">25955268</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stark K, et al.  Distinct pathogenesis of pancreatic cancer microvesicle-associated venous thrombosis identifies newantithrombotic targets in vivo. Arteriosclerosis, thrombosis, Vasc. Biol. 2018;38:772–786.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29419408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelialmesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20:576–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3487108</ArticleId>
            <ArticleId IdType="pubmed">22094253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo Y, Cui W, Pei Y, Xu D. Platelets promote invasion and induce epithelial to mesenchymal transition in ovariancancer cells by TGF-? signaling pathway. Gynecol. Oncol. 2019;153:639–650.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30928020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiong G, et al.  Hsp47 promotes cancer metastasis by enhancing collagen-dependent cancer cell-platelet interaction. Proc. Natl Acad. Sci. USA. 2020;117:3748–3758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7035603</ArticleId>
            <ArticleId IdType="pubmed">32015106</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Egan K, Cooke N, Kenny D. Living in shear: platelets protect cancer cells from shear induced damage. Clin. Exp. Metastasis. 2014;31:697–704.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24942131</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haemmerle M, et al.  Platelets reduce anoikis and promote metastasis by activating YAP1 signaling. Nat. Commun. 2017;8:310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5566477</ArticleId>
            <ArticleId IdType="pubmed">28827520</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nieswandt B, Hafner M, Echtenacher B, Männel DN. Lysis of tumor cells by natural killer cells in mice is impededby platelets. Cancer Res. 1999;59:1295–1300.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10096562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Placke T, et al.  Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumorreactivity of natural killer immune cells. Cancer Res. 2012;72:440–448.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22127925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D therebyinhibiting natural killer cell antitumor reactivity. Cancer Res. 2009;69:7775–7783.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19738039</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maurer S, et al.  Platelet-mediated shedding of NKG2D ligands impairs NK cell immune-surveillance of tumor cells. Oncoimmunology. 2018;7:e1364827.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5749664</ArticleId>
            <ArticleId IdType="pubmed">29308299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Placke T, Salih HR, Kopp HG. GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. J. Immunol. 2012;189:154–160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22649191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren J, et al.  Platelet TLR4-ERK5 axis facilitates net-mediated capturing of circulating tumor cells and distant metastasisafter surgical stress. Cancer Res. 2021;81:2373–2385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8137664</ArticleId>
            <ArticleId IdType="pubmed">33687949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rachidi S, et al.  Platelets subvert T cell immunity against cancer via GARP-TGFβ axis. Sci. Immunol. 2017;2:7911–7937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5539882</ArticleId>
            <ArticleId IdType="pubmed">28763790</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xiang B, et al.  Platelets protect from septic shock by inhibiting macrophage-dependent inflammation via thecyclooxygenase 1 signalling pathway. Nat. Commun. 2013;4:2657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4217311</ArticleId>
            <ArticleId IdType="pubmed">24150174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins.Int. J. Cell Biol. 2012;2012:676731.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3296185</ArticleId>
            <ArticleId IdType="pubmed">22505933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lonsdorf AS, et al.  Engagement of αIIbβ3 (GPIIb/IIIa) with ανβ3 integrin mediates interaction of melanoma cells with platelets: a connection to hematogenous metastasis. J. Biol. Chem. 2012;287:2168–2178.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3265895</ArticleId>
            <ArticleId IdType="pubmed">22102277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coupland LA, Chong BH, Parish CR. Platelets and P-selectin control tumor cell metastasis in an organ-specificmanner and independently of NK cells. Cancer Res. 2012;72:4662–4671.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22836751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumorcelltransendothelial migration and metastasis via P2Y2 receptor. Cancer Cell. 2013;24:130–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23810565</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mammadova-Bach E, et al.  Platelet integrin ?6?1 controls lung metastasis through direct binding to cancer cell-derivedADAM9. JCI Insight. 2016;1:e88245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5033851</ArticleId>
            <ArticleId IdType="pubmed">27699237</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ward Y, et al.  Platelets promote metastasis via binding tumor CD97 leading to bidirectional signaling that coordinatestransendothelial migration. Cell Rep. 2018;23:808–822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6574118</ArticleId>
            <ArticleId IdType="pubmed">29669286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mammadova-Bach E, et al.  Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derivedgalectin-3. Blood. 2020;135:1146–1160.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32040544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu Y, et al.  Blockade of platelets using tumor-specific NO-releasing nanoparticles prevents tumor metastasis and reversestumor immunosuppression. ACS Nano. 2020;14:9780–9795.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32806062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassetta L, et al.  Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation. J. Immunother. Cancer. 2020;8:1223–1235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7481096</ArticleId>
            <ArticleId IdType="pubmed">32907925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Q, Liao Q, Zhao Y. Myeloid-derived suppressor cells (MDSC) facilitate distant metastasis of malignancies byshielding circulating tumor cells (CTC) from immune surveillance. Med. Hypotheses. 2016;87:34–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26826638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiménez-Cortegana C, et al.  Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. J. Immunother. Cancer. 2021;9:2323–2334.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34158317</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sprouse ML, et al.  PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/nodal signaling. Int. J. Mol. Sci. 2019;20:1916–1935.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6514876</ArticleId>
            <ArticleId IdType="pubmed">31003475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 2019;18:99–115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30470818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaggioli C, et al.  Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading andfollowing cells. Nat. Cell Biol. 2007;9:1392–1400.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18037882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Duda DG, et al.  Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl Acad. Sci. USA. 2010;107:21677–21682.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3003109</ArticleId>
            <ArticleId IdType="pubmed">21098274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ortiz-Otero N, et al.  Cancer associated fibroblasts confer shear resistance to circulating tumor cells during prostate cancermetastatic progression. Oncotarget. 2020;11:1037–1050.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7105166</ArticleId>
            <ArticleId IdType="pubmed">32256977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ao Z, et al.  Identification of cancer-associated fibroblasts in circulating blood from patients with metastatic breast cancer. Cancer Res. 2015;75:4681–4687.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26471358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang, R. et al. Rapid isolation of circulating cancer associated fibroblasts by acoustic microstreaming for assessing metastatic propensity of breast cancer patients. Lab. Chip 969-981 (2020).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33351008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen Z, Wu A, Chen X. Current detection technologies for circulating tumor cells. Chem. Soc. Rev. 2017;46:2038–2056.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5598784</ArticleId>
            <ArticleId IdType="pubmed">28393954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vona G, et al.  Isolation by size of epithelial tumor cells-a new method for the immunomorphological and molecularcharacterization of circulating tumor cells. Am. J. Pathol. 2000;156:57–63.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1868645</ArticleId>
            <ArticleId IdType="pubmed">10623654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harouaka RA, et al.  Flexible micro spring array device for high-throughput enrichment of viable circulating tumor cells. Clin. Chem. 2014;60:323–333.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24132944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenberg R, et al.  Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumorcells in blood. Cytometry. 2002;49:150–158.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12454978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta V, et al.  ApoStream(), a new dielectrophoretic device for antibody independent isolation and recovery of viablecancer cells from blood. Biomicrofluidics. 2012;6:24133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3396706</ArticleId>
            <ArticleId IdType="pubmed">23805171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sajay BN, et al.  Microfluidic platform for negative enrichment of circulating tumor cells. Biomed. Microdevices. 2014;16:537–548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24668439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allard WJ, et al.  Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects orpatients with nonmalignant diseases. Clin. Cancer Res. 2004;10:6897–6904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15501967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Talasaz AH, et al.  Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood usinga magnetic sweeper device. Proc. Natl Acad. Sci. USA. 2009;106:3970–3975.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2645911</ArticleId>
            <ArticleId IdType="pubmed">19234122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S, et al.  Enrichment and enumeration of circulating tumor cells by efficient depletion of leukocyte fractions. Clin. Chem. Lab. Med. 2015;53:337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25568985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nasiri R, et al.  Microfluidic-based approaches in targeted cell/particle separation based on physical properties: fundamentalsand applications. Small. 2020;16:e2000171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32529791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagrath S, et al.  Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature. 2007;450:1235–1239.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3090667</ArticleId>
            <ArticleId IdType="pubmed">18097410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Park MH, et al.  Enhanced isolation and release of circulating tumor cells using nanoparticle binding and ligand exchangein a microfluidic chip. J. Am. Chem. Soc. 2017;139:2741–2749.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5506378</ArticleId>
            <ArticleId IdType="pubmed">28133963</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fachin F, et al.  Monolithic chip for high-throughput blood cell depletion to sort rare circulating tumor cells. Sci. Rep. 2017;7:10936–10946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5589885</ArticleId>
            <ArticleId IdType="pubmed">28883519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang X, Zhu Z, Xiang N, Long F, Ni Z. Automated microfluidic instrument for label-free and high-throughput cellseparation. Anal. Chem. 2018;90:4212–4220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29493225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia Z, et al.  Single-cell genetic analysis of lung tumor cells based on self-driving micro-cavity array chip. Talanta. 2021;226:122172.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33676714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, et al.  A fully automated and integrated microfluidic system for efficient ctc detection and its application inhepatocellular carcinoma screening and prognosis. ACS Appl. Mater. Interfaces. 2021;13:30174–30186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34142547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee J, Kwak B. Simultaneous on-chip isolation and characterization of circulating tumor cell sub-populations. Biosens. Bioelectron. 2020;168:112564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32892118</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee AC, et al.  OPENchip: an on-chip in situ molecular profiling platform for gene expression analysis and oncogenicmutation detection in single circulating tumour cells. Lab Chip. 2020;20:912–922.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32057051</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, Li M, Gao X, Chen Y, Liu T. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. J. Hematol. Oncol. 2019;12:137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6918551</ArticleId>
            <ArticleId IdType="pubmed">31847897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jia F, et al.  Novel peptide-based magnetic nanoparticle for mesenchymal circulating tumor cells detection. Anal. Chem. 2021;93:5670–5675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33788544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ding P, et al.  Tannic acid (TA)-functionalized magnetic nanoparticles for EpCAM-independent circulating tumor cell(CTC) isolation from patients with different cancers. ACS Appl. Mater. Interfaces. 2021;13:3694–3700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33442969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li F, et al.  Nondestructive capture, release, and detection of circulating tumor cells with cystamine-mediated folic aciddecorated magnetic nanospheres. J. Mater. Chem. B. 2020;8:9971–9979.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33174893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vajhadin F, et al.  MXene-based cytosensor for the detection of HER2-positive cancer cells using CoFe2O4@Ag magneticnanohybrids conjugated to the HB5 aptamer. Biosens. Bioelectron. 2021;195:113626.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34543916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilson RE, et al.  Immunomagnetic capture and multiplexed surface marker detection of circulating tumor cells withmagnetic multicolor surface-enhanced Raman scattering nanotags. ACS Appl. Mater. Interfaces. 2020;12:47220–47232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32966038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, Luo J, Jiang X, Li X, Yang M. Gold nanoparticle-modified black phosphorus nanosheets with improvedstability for detection of circulating tumor cells. Mikrochim. Acta. 2020;187:397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32564257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dou B, Xu L, Jiang B, Yuan R, Xiang Y. Aptamer-functionalized and gold nanoparticle array-decorated magneticgraphene nanosheets enable multiplexed and sensitive electrochemical detection of rare circulating tumor cells in whole blood. Anal. Chem. 2019;91:10792–10799.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31310099</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheng W, Chen T, Tan W, Fan ZH. Multivalent DNA nanospheres for enhanced capture of cancer cells inmicrofluidic devices. ACS Nano. 2013;7:7067–7076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3785240</ArticleId>
            <ArticleId IdType="pubmed">23837646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al.  Gold nanorods-mediated efficient synergistic immunotherapy for detection and inhibition of postoperativetumor recurrence. Acta Pharm. Sin. B. 2021;11:1978–1992.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8343192</ArticleId>
            <ArticleId IdType="pubmed">34386332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang J, et al.  Sensitive signal amplifying a diagnostic biochip based on a biomimetic periodic nanostructure for detectingcancer exosomes. ACS Appl. Mater. Interfaces. 2020;12:33473–33482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32603586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cui H, et al.  Rapid and efficient isolation and detection of circulating tumor cells based on ZnS:Mn(2+) quantum dots andmagnetic nanocomposites. Talanta. 2019;202:230–236.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31171175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, et al.  Reversible capturing and voltammetric determination of circulating tumor cells using two-dimensionalnanozyme based on PdMo decorated with gold nanoparticles and aptamer. Mikrochim. Acta. 2021;188:319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34476628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su Y, et al.  Antibody-functional microsphere-integrated filter chip with inertial microflow for size-immune-capturing anddigital detection of circulating tumor cells. ACS Appl Mater. Interfaces. 2019;11:29569–29578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31361117</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Husemann Y, et al.  Systemic spread is an early step in breast cancer. Cancer Cell. 2008;13:58–68.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18167340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hosseini H, et al.  Early dissemination seeds metastasis in breast cancer. Nature. 2016;540:552–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5390864</ArticleId>
            <ArticleId IdType="pubmed">27974799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rhim AD, et al.  Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions. Gastroenterology. 2014;146:647–651.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4514438</ArticleId>
            <ArticleId IdType="pubmed">24333829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamaguchi J, et al.  Premalignant pancreatic cells seed stealth metastasis in distant organs in mice. Oncogene. 2021;40:2273–2284.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33649537</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrière G, Riouallon A, Renaudie J, Tartary M, Rigaud M. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer. 2012;12:114–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3364860</ArticleId>
            <ArticleId IdType="pubmed">22443102</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thery L, et al.  Circulating tumor cells in early breast. Cancer JNCI Cancer Spectr. 2019;3:pkz026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6649836</ArticleId>
            <ArticleId IdType="pubmed">31360902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paoletti C, et al.  Circulating tumor cell clusters in patients with metastatic breast cancer: a SWOG S0500 translationalmedicine study. Clin. Cancer Res. 2019;25:6089–6097.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6801082</ArticleId>
            <ArticleId IdType="pubmed">31358544</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magbanua MJM, et al.  Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bonemarrow predicts adverse outcome in early breast cancer. Clin. Cancer Res. 2019;25:5388–5397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6726564</ArticleId>
            <ArticleId IdType="pubmed">31142502</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magbanua MJM, et al.  Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breastcancer patients who received letrozole with or without Bevacizumab. Clin. Cancer Res. 2020;26:4911–4920.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7501177</ArticleId>
            <ArticleId IdType="pubmed">32586939</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bortolini Silveira A, et al.  Multimodal liquid biopsy for early monitoring and outcome prediction of chemotherapy inmetastatic breast cancer. NPJ Breast Cancer. 2021;7:115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8429692</ArticleId>
            <ArticleId IdType="pubmed">34504096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paoletti C, et al.  Circulating tumor cell number and endocrine therapy index in ER positive metastatic breast cancerpatients. NPJ Breast Cancer. 2021;7:77.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8196036</ArticleId>
            <ArticleId IdType="pubmed">34117261</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magbanua MJM, et al.  Serial analysis of circulating tumor cells in metastatic breast cancer receiving first-linechemotherapy. J. Natl Cancer Inst. 2021;113:443–452.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8023821</ArticleId>
            <ArticleId IdType="pubmed">32770247</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Kruijff IE, et al.  Circulating tumor cell enumeration and characterization in metastatic castration-resistant prostate cancer patients treated with cabazitaxel. Cancers. 2019;11:1212–1225.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6721462</ArticleId>
            <ArticleId IdType="pubmed">31434336</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cieslikowski WA, et al.  Circulating tumor cells as a marker of disseminated disease in patients with newly diagnosed high-risk prostate cancer. Cancers. 2020;12:160–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7017349</ArticleId>
            <ArticleId IdType="pubmed">31936460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basso U, et al.  Prognostic role of circulating tumor cells in metastatic renal cell carcinoma: a large, multicenter, prospectivetrial. Oncologist. 2021;26:740–750.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8417856</ArticleId>
            <ArticleId IdType="pubmed">34077597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chemi F, et al.  Pulmonary venous circulating tumor cell dissemination before tumor resection and disease relapse. Nat. Med. 2019;25:1534–1539.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6986897</ArticleId>
            <ArticleId IdType="pubmed">31591595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messaritakis I, et al.  Characterization of DLL3-positive circulating tumor cells (CTCs) in patients with small cell lungcancer (SCLC) and evaluation of their clinical relevance during front-line treatment. Lung Cancer. 2019;135:33–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31447000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun YF, et al.  Postoperative circulating tumor cells: an early predictor of extrahepatic metastases in patients withhepatocellular carcinoma undergoing curative surgical resection. Cancer Cytopathol. 2020;128:733–745.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32501632</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matsushita D, et al.  Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negativemetastatic gastric cancer. Cancer Chemother. Pharm. 2021;87:789–797.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33641065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sastre J, et al.  Association between baseline circulating tumor cells, molecular tumor profiling, and clinical characteristics ina large cohort of chemo-naive metastatic colorectal cancer patients prospectively collected. Clin. Colorectal Cancer. 2020;19:e110–e116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32278676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidard FC, et al.  Circulating tumor cells in breast cancer patients treated by neoadjuvant chemotherapy: a meta-analysis. J. Natl Cancer Inst. 2018;110:560–567.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29659933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murlidhar V, et al.  Poor prognosis indicated by venous circulating tumor cell clusters in early-stage lung cancers. CancerRes. 2017;77:5194–5206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5600850</ArticleId>
            <ArticleId IdType="pubmed">28716896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jansson S, Bendahl PO, Larsson AM, Aaltonen KE, Ryden L. Prognostic impact of circulating tumor cellapoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. BMC Cancer. 2016;16:433.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4938919</ArticleId>
            <ArticleId IdType="pubmed">27390845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, et al.  Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. BreastCancer Res. Treat. 2017;161:83–94.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27771841</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang C, et al.  Improved prognostic stratification using circulating tumor cell clusters in patients with metastatic castration-resistant prostate cancer. Cancers. 2021;13:268–280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7828213</ArticleId>
            <ArticleId IdType="pubmed">33450815</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lozano R, et al.  Value of early circulating tumor cells dynamics to estimate docetaxel benefit in metastatic castration-resistant prostate cancer (mCRPC) patients. Cancers. 2021;13:2334–2344.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8151844</ArticleId>
            <ArticleId IdType="pubmed">34066080</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su P, et al.  Mesenchymal and phosphatase of regenerating liver-3 status in circulating tumor cells may serve as a crucialprognostic marker for assessing relapse or metastasis in postoperative patients with colorectal cancer. Clin. Transl. Gastroenterol. 2020;11:e00265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7743843</ArticleId>
            <ArticleId IdType="pubmed">33512811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strati A, Nikolaou M, Georgoulias V, Lianidou ES. Prognostic significance of TWIST1, CD24, CD44, and ALDH1 transcript quantification in EpCAM-positive circulating tumor cells from early stage breast cancer patients. Cells. 2019;8:652–667.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6679222</ArticleId>
            <ArticleId IdType="pubmed">31261917</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadaki MA, et al.  Clinical relevance of immune checkpoints on circulating tumor cells in breast cancer. Cancers. 2020;12:376–396.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7072621</ArticleId>
            <ArticleId IdType="pubmed">32041353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang XQ, Liu B, Li BY, Wang T, Chen DQ. Effect of CTCs and INHBA level on the effect and prognosis ofdifferent treatment methods for patients with early breast cancer. Eur. Rev. Med. Pharm. Sci. 2020;24:12735–12740.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33378021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Graf RP, et al.  Clinical utility of the nuclear-localized AR-V7 biomarker in circulating tumor cells in improving physiciantreatment choice in castration-resistant prostate cancer. Eur. Urol. 2020;77:170–177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7472426</ArticleId>
            <ArticleId IdType="pubmed">31648903</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei T, et al.  Vimentin-positive circulating tumor cells as a biomarker for diagnosis and treatment monitoring in patientswith pancreatic cancer. Cancer Lett. 2019;452:237–243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30905814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Economos C, Morrissey C, Vessella RL. Circulating tumor cells as a marker of response: implications for determiningtreatment efficacy and evaluating new agents. Curr. Opin. Urol. 2012;22:190–196.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22328019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, Wu S, Bai F. Molecular characterization of circulating tumor cells-from bench to bedside. Semin. Cell Dev. Biol. 2018;75:88–97.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28899718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massard C, et al.  RECIST response and variation of circulating tumour cells in phase 1 trials: a prospective multicentricstudy. Eur. J. Cancer. 2017;83:185–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28743036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ntzifa A, Kotsakis A, Georgoulias V, Lianidou E. Detection of EGFR mutations in plasma cfDNA and paired CTCs of NSCLC patients before and after osimertinib therapy using crystal digital PCR. Cancers. 2021;13:2376–2394.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8197887</ArticleId>
            <ArticleId IdType="pubmed">34073111</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan X, Zhang X. Utility of circulating tumor cells and DNA in the management of advanced colorectal cancer. FutureOncol. 2020;16:1289–1299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32379501</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garrido-Navas MC, et al.  The polemic diagnostic role of tp53 mutations in liquid biopsies from breast, colon and lung cancers. Cancers. 2020;12:3343–3359.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7696715</ArticleId>
            <ArticleId IdType="pubmed">33198130</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mong J, Tan MH. Size-based enrichment technologies for non-cancerous tumor-derived cells in blood. TrendsBiotechnol. 2018;36:511–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29559166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristofanilli M, et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N. Engl. J. Med. 2004;351:781–791.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15317891</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu MC, et al.  Circulating tumor cells: a useful predictor of treatment efficacy in metastatic breast cancer. J. Clin. Oncol. 2009;27:5153–5159.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4879719</ArticleId>
            <ArticleId IdType="pubmed">19752342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pestrin M, et al.  Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib inpatients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. BreastCancer Res. Treat. 2012;134:283–289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22476856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierga, J. Y. et al. High independent prognostic and predictive value of circulating tumor cells compared with serum tumormarkers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients. Ann. Oncol. 23, 618-624</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21642515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giordano A, et al.  Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of predictionin HER2-positive disease treated with targeted therapy. Ann. Oncol. 2012;23:1144–1150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21965473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang ZF, et al.  Circulating tumor cells predict progression-free and overall survival in Chinese patients with metastaticbreast cancer, HER2-positive or triple-negative (CBCSG004): a multicenter, double-blind, prospective trial. Ann. Oncol. 2013;24:2766–2772.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23857960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pierga JY, et al.  Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: theLANDSCAPE trial. Ann. Oncol. 2013;24:2999–3004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24013510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smerage JB, et al.  Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J. Clin. Oncol. 2014;32:3483–3489.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4209100</ArticleId>
            <ArticleId IdType="pubmed">24888818</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall C, et al.  Circulating tumor cells after neoadjuvant chemotherapy in stage I-III triple-negative breast cancer. Ann. Surg. Oncol. 2015;22:S552–S558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25968619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hall CS, et al.  Prognostic value of circulating tumor cells identified before surgical resection in nonmetastatic breastcancer patients. J. Am. Coll. Surg. 2016;223:20–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5868486</ArticleId>
            <ArticleId IdType="pubmed">27049782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riethdorf S, et al.  Prognostic impact of circulating tumor cells for breast cancer patients treated in the neoadjuvant“geparquattro” trial. Clin. Cancer Res. 2017;23:5384–5393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28679772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sparano J, et al.  Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: asecondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:1700–1706.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6385891</ArticleId>
            <ArticleId IdType="pubmed">30054636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rossi G, et al.  Cell-free DNA and circulating tumor cells: comprehensive liquid biopsy analysis in advanced breast cancer. Clin. Cancer Res. 2018;24:560–568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29180605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Trapp E, et al.  Presence of circulating tumor cells in high-risk early breast cancer during follow-up and prognosis. J. NatlCancer Inst. 2019;111:380–387.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30312434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radovich M, et al.  Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy withdisease recurrence in patients with triple-negative breast cancer: preplanned secondary analysis of the BRE12-158 randomizedclinical trial. JAMA Oncol. 2020;6:1410–1415.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7349081</ArticleId>
            <ArticleId IdType="pubmed">32644110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou J, et al.  Epithelial-mesenchymal transition status of circulating tumor cells in breast cancer and its clinical relevance. Cancer Biol. Med. 2020;17:169–180.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7142848</ArticleId>
            <ArticleId IdType="pubmed">32296584</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Le Du,F, et al.  EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition andcancer stem cell phenotypes using ApoStream(R) in patients with breast cancer treated with primary systemic therapy. PLoS One. 2020;15:e0229903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7098555</ArticleId>
            <ArticleId IdType="pubmed">32214335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang SR, et al.  Mesenchymal phenotype of circulating tumor cells is associated with distant metastasis in breast cancerpatients. Cancer Manag. Res. 2017;9:691–700.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5703158</ArticleId>
            <ArticleId IdType="pubmed">29200889</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bulfoni M, et al.  In patients with metastatic breast cancer the identification of circulating tumor cells in epithelial-tomesenchymaltransition is associated with a poor prognosis. Breast Cancer Res. 2016;18:30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4784394</ArticleId>
            <ArticleId IdType="pubmed">26961140</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papadaki MA, et al.  Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features arechemoresistant and predictive of poor outcome in metastatic breast Cancer. Mol. Cancer Ther. 2019;18:437–447.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30401696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>de Kruijff IE, et al.  Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer. Int. J. Cancer. 2019;145:1083–1089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30761532</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bock C, et al.  Distinct expression of cytokeratin, N-cadherin and CD133 in circulating tumor cells of metastatic breastcancer patients. Future Oncol. 2014;10:1751–1765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25303055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodman OB, et al.  Circulating tumor cells in patients with castration-resistant prostate cancer baseline values andcorrelation with prognostic factors. Cancer Epidemiol. Biomark. Prev. 2009;18:1904–1913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19505924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goldkorn A, et al.  Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase iii trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2014;32:1136–113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3970171</ArticleId>
            <ArticleId IdType="pubmed">24616308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satelli A, et al.  Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as aprognostic marker in cancer patients. Sci. Rep. 2016;6:28910.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4929464</ArticleId>
            <ArticleId IdType="pubmed">27363678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen J, et al.  Metabolic reprogramming-based characterization of circulating tumor cells in prostate cancer. J. Exp. Clin. Cancer Res. 2018;37:127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6025832</ArticleId>
            <ArticleId IdType="pubmed">29954422</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu H, Ding J, Wu Y, Wu D, Qi J. Prospective study of the clinical impact of epithelial and mesenchymal circulatingtumor cells in localized prostate cancer. Cancer Manag. Res. 2020;12:4549–4560.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7304675</ArticleId>
            <ArticleId IdType="pubmed">32606948</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonarakis ES, et al.  AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 2014;371:1028–1038.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4201502</ArticleId>
            <ArticleId IdType="pubmed">25184630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okegawa T, et al.  AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate andenzalutamide treatment in castration-resistant prostate cancer patients. Prostate. 2018;78:576–582.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29508425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tagawa ST, et al.  Expression of AR-V7 and ARv(567es) in circulating tumor cells correlates with outcomes to taxanetherapy in men with metastatic prostate cancer treated in TAXYNERGY. Clin. Cancer Res. 2019;25:1880–1888.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6432911</ArticleId>
            <ArticleId IdType="pubmed">30301829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markou A, et al.  PIM-1 Is Overexpressed at a high frequency in circulating tumor cells from metastatic castration-resistant prostate cancer patients. Cancers. 2020;12:1188–1201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7281625</ArticleId>
            <ArticleId IdType="pubmed">32397108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu S, et al.  Combined cell surface carbonic anhydrase 9 and CD147 antigens enable high-efficiency capture of circulatingtumor cells in clear cell renal cell carcinoma patients. Oncotarget. 2016;7:59877–59891.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5312355</ArticleId>
            <ArticleId IdType="pubmed">27494883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naoe M, et al.  Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer. 2007;109:1439–1445.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17326057</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gallagher DJ, et al.  Detection of circulating tumor cells in patients with urothelial cancer. Ann. Oncol. 2009;20:305–308.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18836088</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rink M, et al.  Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladdercancer. BJU Int. 2011;107:1668–1675.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20735381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gazzaniga P, et al.  Prognostic value of circulating tumor cells in nonmuscle invasive bladder cancer: a CellSearch analysis. Ann. Oncol. 2012;23:2352–2356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22351740</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen SJ, et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival inpatients with metastatic colorectal cancer. J. Clin. Oncol. 2008;26:3213–3221.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18591556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen SJ, et al.  Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann. Oncol. 2009;20:1223–1229.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19282466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang W, et al.  Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancerprognosis. Cell Oncol. 2018;41:495–504.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29949050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu F, et al.  Associations between the epithelial-mesenchymal transition phenotypes of circulating tumor cells and theclinicopathological features of patients with colorectal cancer. Dis. Markers. 2017;2017:9474532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5752983</ArticleId>
            <ArticleId IdType="pubmed">29430076</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao R, et al.  Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells fromcolorectal cancer. Oncotarget. 2017;8:9293–9302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5354732</ArticleId>
            <ArticleId IdType="pubmed">28030836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ning Y, et al.  Clinical relevance of EMT and stem-like gene expression in circulating tumor cells of metastatic colorectalcancer patients. Pharmacogenom. J. 2018;18:29–34.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7505126</ArticleId>
            <ArticleId IdType="pubmed">27503579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bao H, et al.  High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells isassociated with poor clinical response to the immune checkpoint inhibitor nivolumab. Oncol. Lett. 2018;15:3061–3067.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5778830</ArticleId>
            <ArticleId IdType="pubmed">29435038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shen C, Hu L, Xia L, Li Y. Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral bloodof colorectal cancer patients. Jpn. J. Clin. Oncol. 2008;38:770–776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18845519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimada R, Iinuma H, Akahane T, Horiuchi A, Watanabe T. Prognostic significance of CTCs and CSCs of tumordrainage vein blood in Dukes' stage B and C colorectal cancer patients. Oncol. Rep. 2012;27:947–953.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3583432</ArticleId>
            <ArticleId IdType="pubmed">22267181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbazan J, et al.  A multimarker panel for circulating tumor cells detection predicts patient AQ5 outcome and therapyresponse in metastatic colorectal cancer. Int. J. Cancer. 2014;135:2633–2643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24752533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokobori T, et al.  Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transitionand is associated with colorectal cancer prognosis. Cancer Res. 2013;73:2059–2069.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23378342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bian J, Yan K, Liu N, Xu X. Correlations between circulating tumor cell phenotyping and 18F-fluorodeoxyglucosepositron emission tomography uptake in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 2020;146:2621–2630.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32661602</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong J, et al.  Detection of circulating tumor cell molecular subtype in pulmonary vein predicting prognosis of stage I-IIInon-small cell lung cancer patients. Front Oncol. 2019;9:1139.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6830362</ArticleId>
            <ArticleId IdType="pubmed">31737568</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manjunath Y, et al.  PD-L1 Expression with epithelial mesenchymal transition of circulating tumor cells is associated with poor survival in curatively resected non-small cell lung cancer. Cancers. 2019;11:806–816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6628040</ArticleId>
            <ArticleId IdType="pubmed">31212653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Krebs MG, et al.  Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lungcancer. J. Clin. Oncol. 2011;29:1556–1563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21422424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Punnoose EA, et al.  Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer:association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin. Cancer Res. 2012;18:2391–2401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22492982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang N, et al.  Efficient isolation and quantification of circulating tumor cells in non-small cell lung cancer patients usingpeptide-functionalized magnetic nanoparticles. J. Thorac. Dis. 2020;12:4262–4273.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7475553</ArticleId>
            <ArticleId IdType="pubmed">32944338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamminga M, et al.  Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumorresponse to checkpoint inhibitors. J. Immunother. Cancer. 2019;7:173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6617698</ArticleId>
            <ArticleId IdType="pubmed">31291995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamminga M, et al.  Analysis of released circulating tumor cells during surgery for non-small cell lung cancer. Clin. CancerRes. 2020;26,:1656–1666.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31772122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frick MA, et al.  Circulating tumor cells are associated with recurrent disease in patients with early-stage non-small celllung cancer treated with stereotactic body radiotherapy. Clin. Cancer Res. 2020;26:2372–2380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31969332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiltermann TJN, et al.  Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor. Ann. Oncol. 2012;23:2937–2942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22689177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou JM, et al.  Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patientsundergoing chemotherapy. Am. J. Pathol. 2009;175:808–816.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2716975</ArticleId>
            <ArticleId IdType="pubmed">19628770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hou JM, et al.  Clinical significance and molecular characteristics of circulating tumor cells and circulating tumormicroemboli in patients with small-cell lung cancer. J. Clin. Oncol. 2012;30:525–532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22253462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang CH, et al.  A multicenter pilot study examining the role of circulating tumor cells as a blood-based tumor marker inpatients with extensive small-cell lung cancer. Front Oncol. 2014;4:271.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4196518</ArticleId>
            <ArticleId IdType="pubmed">25353007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Naito T, et al.  Prognostic impact of circulating tumor cells in patients with small cell lung cancer. J. Thorac. Oncol. 2012;7:512–519.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22258473</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Normanno N, et al.  Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer. Lung Cancer. 2014;85:314–319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24882383</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messaritakis I, et al.  Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small celllung cancer. PLoS One. 2017;12:e0181211.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5515424</ArticleId>
            <ArticleId IdType="pubmed">28719656</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidard FC, et al.  Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study tothe LAP 07 trial. Ann. Oncol. 2013;24:2057–2061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23676420</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Court CM, et al.  Circulating tumor cells predict occult metastatic disease and prognosis in pancreatic cancer. Ann. Surg. Oncol. 2018;25:1000–1008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5896564</ArticleId>
            <ArticleId IdType="pubmed">29442211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gall TM, et al.  Reduced dissemination of circulating tumor cells with no-touch isolation surgical technique in patients withpancreatic cancer. JAMA Surg. 2014;149:482–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24599353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hugenschmidt H, et al.  Circulating tumor cells are an independent predictor of shorter survival in patients undergoingresection for pancreatic and periampullary adenocarcinoma. Ann. Surg. 2020;271:549–558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30216219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okubo K, et al.  Clinical impact of circulating tumor cells and therapy response in pancreatic cancer. Eur. J. Surg. Oncol. 2017;43:1050–1055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28233633</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dong X, et al.  Spatial heterogeneity in epithelial to mesenchymal transition properties of circulating tumor cells associatedwith distant recurrence in pancreatic cancer patients. Ann. Transl. Med. 2020;8:676.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7327339</ArticleId>
            <ArticleId IdType="pubmed">32617296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao XH, et al.  Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells frompancreatic cancer patients: Potential role in clinical practice. World J. Gastroenterol. 2019;25:138–150.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6328963</ArticleId>
            <ArticleId IdType="pubmed">30643364</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu P, et al.  Circulating tumor cells expressing Kruppel-like factor 8 and vimentin as predictors of poor prognosis inpancreatic cancer patients. Cancer Control. 2021;28:10732748211027163.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8361509</ArticleId>
            <ArticleId IdType="pubmed">34378430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ou H, et al.  Circulating tumor cell phenotype indicates poor survival and recurrence after surgery for hepatocellularcarcinoma. Dig. Dis. Sci. 2018;63:2373–2380.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29926241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang PX, et al.  Circulating tumor cells are an indicator for the administration of adjuvant transarterial chemoembolizationin hepatocellular carcinoma: a single-center, retrospective, propensity-matched study. Clin. Transl. Med. 2020;10:e137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7418815</ArticleId>
            <ArticleId IdType="pubmed">32702202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu JJ, et al.  Effect of surgical liver resection on circulating tumor cells in patients with hepatocellular carcinoma. BMCCancer. 2018;18:835.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6102841</ArticleId>
            <ArticleId IdType="pubmed">30126375</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou J, et al.  Preoperative circulating tumor cells to predict microvascular invasion and dynamical detection indicate theprognosis of hepatocellular carcinoma. BMC Cancer. 2020;20:1047.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7603758</ArticleId>
            <ArticleId IdType="pubmed">33129301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou KQ, et al.  Effect of surgical margin on recurrence based on preoperative circulating tumor cell status inhepatocellular carcinoma. EBioMedicine. 2020;62:103107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7658489</ArticleId>
            <ArticleId IdType="pubmed">33181461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu YK, et al.  An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells inhepatocellular carcinoma patients. Hepatol. Int. 2016;10:640–646.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27115761</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Qi LN, et al.  Circulating tumor cells undergoing EMT provide a metric for diagnosis and prognosis of patients withhepatocellular carcinoma. Cancer Res. 2018;78:4731–4744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29915159</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Z, et al.  Correlation between postoperative early recurrence of hepatocellular carcinoma and mesenchymal circulatingtumor cells in peripheral blood. J. Gastrointest. Surg. 2018;22:633–639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5869875</ArticleId>
            <ArticleId IdType="pubmed">29159757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Court CM, et al.  A novel multimarker assay for the phenotypic profiling of circulating tumor cells in hepatocellularcarcinoma. Liver Transpl. 2018;24:946–960.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6097911</ArticleId>
            <ArticleId IdType="pubmed">29624843</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yi B, et al.  The clinical significance of CTC enrichment by GPC3-IML and its genetic analysis in hepatocellular carcinoma. J. Nanobiotechnol. 2021;19:74.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7962223</ArticleId>
            <ArticleId IdType="pubmed">33726759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun YF, et al.  Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq inhepatocellular carcinoma. Nat. Commun. 2021;12:4091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8253833</ArticleId>
            <ArticleId IdType="pubmed">34215748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yin LC, et al.  Twist expression in circulating hepatocellular carcinoma cells predicts metastasis and prognoses. Biomed. Res. Int. 2018;2018:3789613.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6038670</ArticleId>
            <ArticleId IdType="pubmed">30046595</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun YF, et al.  Circulating stem cell-like epithelial cell adhesion molecule-positive tumor cells indicate poor prognosis ofhepatocellular carcinoma after curative resection. Hepatology. 2013;57:1458–1468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23175471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee SJ, et al.  Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer. Int. J. Biol. Markers. 2015;30:e382–e386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26044775</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uenosono Y, et al.  Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119:3984–3991.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23963829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, et al.  A prospective study on the changes and clinical significance of pre-operative and post-operative circulatingtumor cells in resectable gastric cancer. J. Transl. Med. 2018;16:171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6011408</ArticleId>
            <ArticleId IdType="pubmed">29925382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu M, et al.  Prognostic significance of PD-L1 expression on cell-surface vimentin-positive circulating tumor cells in gastriccancer patients. Mol. Oncol. 2020;14:865–881.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7138401</ArticleId>
            <ArticleId IdType="pubmed">31981446</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hatakeyama K, et al.  A novel splice variant of XIAP-associated factor 1 (XAF1) is expressed in peripheral bloodcontaining gastric cancer-derived circulating tumor cells. Gastr. Cancer. 2015;18:751–761.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25216542</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vaiopoulos AG, et al.  Detection of circulating tumor cells in colorectal and gastric cancer using a multiplex PCR assay. Anticancer Res. 2014;34:3083–3092.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24922677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ishiguro Y, et al.  Prognostic significance of circulating tumor cells with mesenchymal phenotypes in patients with gastriccancer: a prospective study. Ann. Surg. Oncol. 2021;28:1178–1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32770296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mimori K, et al.  A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bonemarrow in gastric cancer cases. Ann. Surg. Oncol. 2008;15:2934–2942.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18661187</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y, et al.  Prognostic value of circulating tumor cells detected with the CellSearch system in esophageal cancer patients: asystematic review and meta-analysis. BMC Cancer. 2020;20:581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7310134</ArticleId>
            <ArticleId IdType="pubmed">32571299</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tewari KS, et al.  Circulating tumor cells in advanced cervical cancer: NRG Oncology-Gynecologic Oncology Group study240 (NCT 00803062) Mol. Cancer Ther. 2020;19:2363–2370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7907274</ArticleId>
            <ArticleId IdType="pubmed">32847980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Anand K, et al.  Pilot study of circulating tumor cells in early-stage and metastatic uveal melanoma. Cancers. 2019;11:856–863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6628316</ArticleId>
            <ArticleId IdType="pubmed">31226786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim DD, Yang CS, Chae HD, Kwak SG, Jeon CH. Melanoma antigen-encoding gene family member A1-6and hTERT in the detection of circulating tumor cells following CD45(-) depletion and RNA extraction. Oncol. Lett. 2017;14:837–843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5494678</ArticleId>
            <ArticleId IdType="pubmed">28693240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mego M, et al.  Circulating tumor cells with epithelial-to-mesenchymal transition phenotypes associated with inferioroutcomes in primary breast cancer. Anticancer Res. 2019;39:1829–1837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30952723</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y, et al.  Utility of circulating tumor cells for detection of early-stage luminal a breast cancer. Am. J. Med Sci. 2020;360:543–551.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32690274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefanovic S, et al.  The lack of evidence for an association between cancer biomarker conversion patterns and CTC-status in patients with metastatic breast cancer. Int. J. Mol. Sci. 2020;21:2161–2171.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7139918</ArticleId>
            <ArticleId IdType="pubmed">32245182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jin L, et al.  Evaluation of the diagnostic value of circulating tumor cells with CytoSorter((R)) CTC capture system inpatients with breast cancer. Cancer Med. 2020;9:1638–1647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7050089</ArticleId>
            <ArticleId IdType="pubmed">31908156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shliakhtunou YA. CTCs-oriented adjuvant personalized cytostatic therapy non-metastatic breast cancer patients:continuous non-randomized prospective study and prospective randomized controlled study. Breast Cancer Res. Treat. 2021;186:439–451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7990849</ArticleId>
            <ArticleId IdType="pubmed">33389399</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sieuwerts AM, et al.  AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer:relation with outcome to cabazitaxel. Mol. Oncol. 2019;13:1795–1807.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6670012</ArticleId>
            <ArticleId IdType="pubmed">31180178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schonhoft JD, et al.  Morphology-predicted large-scale transition number in circulating tumor cells identifies achromosomal instability biomarker associated with poor outcome in castration-resistant prostate cancer. Cancer Res. 2020;80:4892–4903.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8428781</ArticleId>
            <ArticleId IdType="pubmed">32816908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armstrong AJ, et al.  Prospective multicenter study of circulating tumor cell AR-V7 and taxane versus hormonal treatment outcomes in metastatic castration-resistant prostate cancer. JCO Precis. Oncol. 2020;4:1285–1301.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7608579</ArticleId>
            <ArticleId IdType="pubmed">33154984</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xu L, et al.  Noninvasive detection of clinically significant prostate cancer using circulating tumor cells. J. Urol. 2020;203:73–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31389764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sperger JM, et al.  Prospective evaluation of clinical outcomes using a multiplex liquid biopsy targeting diverse resistancemechanisms in metastatic prostate cancer. J. Clin. Oncol. 2021;39:2926–2937.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8425833</ArticleId>
            <ArticleId IdType="pubmed">34197212</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, et al.  The significance of detection of circulating tumor cells and BECLIN1 in peripheral blood of patients withrenal cell carcinoma. Crit. Rev. Eukaryot. Gene Expr. 2020;30:483–492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33463915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Z, et al.  Circulating tumor cells can predict the prognosis of patients with non-small cell lung cancer after resection: aretrospective study. Transl. Lung Cancer Res. 2021;10:995–1006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7947419</ArticleId>
            <ArticleId IdType="pubmed">33718038</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang PP, et al.  Circulating tumor cells as a new predictive and prognostic factor in patients with small cell lung cancer. J. Cancer. 2020;11:2113–2122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7052935</ArticleId>
            <ArticleId IdType="pubmed">32127938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ha Y, et al.  Circulating tumor cells are associated with poor outcomes in early-stage hepatocellular carcinoma: aprospective study. Hepatol. Int. 2019;13:726–735.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31691073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, et al.  Circulating tumor cells undergoing EMT are poorly correlated with clinical stages or predictive of recurrencein hepatocellular carcinoma. Sci. Rep. 2019;9:7084.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6506548</ArticleId>
            <ArticleId IdType="pubmed">31068623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheng Y, et al.  Diagnostic value of different phenotype circulating tumor cells in hepatocellular carcinoma. J. Gastrointest. Surg. 2019;23:2354–2361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30805878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lei Y, et al.  Association of preoperative NANOG-positive circulating tumor cell levels with recurrence of hepatocellularcarcinoma. Front. Oncol. 2021;11:601668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8190394</ArticleId>
            <ArticleId IdType="pubmed">34123777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szczepanik A, et al.  CD44(+) cytokeratin-positive tumor cells in blood and bone marrow are associated with poor prognosisof patients with gastric cancer. Gastr. Cancer. 2019;22:264–272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6394724</ArticleId>
            <ArticleId IdType="pubmed">30056567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miki Y, et al.  Circulating CEA-positive and EpCAM-negative tumor cells might be a predictive biomarker for recurrence inpatients with gastric cancer. Cancer Med. 2021;10:521–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7877362</ArticleId>
            <ArticleId IdType="pubmed">33381922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuroda K, et al.  Circulating tumor cells with FGFR2 expression might be useful to identify patients with existing FGFR2-overexpressing tumor. Cancer Sci. 2020;111:4500–4509.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7734156</ArticleId>
            <ArticleId IdType="pubmed">32946655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D, et al.  Prognostic models based on postoperative circulating tumor cells can predict poor tumor recurrence-freesurvival in patients with stage II-III colorectal cancer. J. Cancer. 2019;10:4552–4563.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6746136</ArticleId>
            <ArticleId IdType="pubmed">31528219</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bidard FC, et al.  Circulating tumor cells and circulating tumor DNA detection in potentially resectable metastatic colorectal cancer: a prospective ancillary study to the unicancer Prodige-14 Trial. Cells. 2019;8:516–528.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6627974</ArticleId>
            <ArticleId IdType="pubmed">31142037</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang L, et al.  Circulating tumor cells as an independent prognostic factor in advanced colorectal cancer: a retrospectivestudy in 121 patients. Int. J. Colorectal Dis. 2019;34:589–597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30627849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Messaritakis I, et al.  Evaluation of the role of circulating tumor cells and microsatellite instability status in predicting outcome of advanced CRC patients. J. Pers. Med. 2020;10:235–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7712177</ArticleId>
            <ArticleId IdType="pubmed">33217974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan RJ, et al.  Detection and clinical value of circulating tumor cells as an assisted prognostic marker in colorectal cancerpatients. Cancer Manag. Res. 2021;13:4567–4578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8197664</ArticleId>
            <ArticleId IdType="pubmed">34135633</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
